eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Reckitt Benckiser Healthcare (UK) Ltd

Freepost, RSBU-TEBT-GSTU, Reckitt Benckiser, Kingston Upon Thames, KT2 6LZ, UK
Telephone: +44 (0)500 455 456
WWW: http://www.reckittbenckiser.com
Medical Information Direct Line: +44 (0)500 455 456
Customer Care direct line: +44 (0)500 455 456

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 23/07/2010
SPC Bonjela Teething Gel


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Bonjela Teething Gel.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient

%w/w

Specification

Lidocaine hydrochloride1

0.33

BP

Cetalkonium chloride

0.01

HSE

1Equivalent to 0.27% w/w of Lidocaine base.


Go to top of the page
3. PHARMACEUTICAL FORM

Water soluble viscous gel.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the relief of pain and discomfort associated with infant teething.


Go to top of the page
4.2 Posology and method of administration

Topical application to the gums.

Infants and young children:

Apply a small amount of Bonjela Teething Gel with a clean little finger to the affected area and rub in gently. Repeat every three hours if necessary.

Not recommended for infants under two months.

 

 

 

 

Adults and elderly:

Not intended for adult use.


Go to top of the page
4.3 Contraindications

Known hypersensitivity to anaesthetics of the amide type.


Go to top of the page
4.4 Special warnings and precautions for use

To be used with caution in patients with hepatic or cardiac dysfunction.

Label warnings: Do not use more than every 3 hours. Do not exceed the stated dose. Not recommended for infants under two months. Keep out of reach of children. If symptoms persist consult your doctor.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Concurrent use of either cimetidine or propranolol increases the risk of Lidocaine toxicity. Lidocaine is antagonised by those diuretics which cause hypokalaemia.


Go to top of the page
4.6 Pregnancy and lactation

Not applicable.


Go to top of the page
4.7 Effects on ability to drive and use machines

Not applicable.


Go to top of the page
4.8 Undesirable effects

There have been a few cases of contact dermatitis and methaemoglobinaemia.


Go to top of the page
4.9 Overdose

The toxic effects of Lidocaine are directly related to blood concentrations. Symptoms are dizziness, cyanosis due to methaemoglobinaemia, fall of blood pressure, muscular tremors, convulsions, coma, irregular and weak breathing, cardiac standstill and bronchial spasm. Removal of the ingested drug by induced emesis followed by activated charcoal is only useful if the patient is seen within 30 minutes of ingestion. The airway must be maintained and artificial respiration with oxygen given until convulsions or depression are controlled and blood pressure and pulse return to normal.

Convulsions can be controlled with diazepam (0.1mg/kg i.v.) or succinylcholine chloride (10-50mg i.v. slowly). Perform artificial respiration with oxygen until convulsions are controlled and continue giving oxygen until blood pressure and pulse return to normal. Adequate arterial oxygen saturation must be maintained. If convulsions are not continuous the administration of oxygen may be sufficient to maintain the patient until the blood level of Lidocaine falls. Do not give stimulants. The methaemoglobinaemia can be treated by methylene blue (1%, 0.1 ml/kg, i.v. over ten minutes). Treat fall in blood pressure by postural means (head down, feet raised, supine position) or with i.v. saline or blood transfusion if shock threatens. The critical period does not exceed one hour.

Suppression of pharyngeal sensation with concomitant effects on swallowing may theoretically result from excessive topical oral use of Bonjela Teething Gel. Such an effect has been reported in an adult who gargled and swallowed 5 ml of a 2% Lidocaine hydrochloride solution (equivalent to 100mg of Lidocaine).However, assuming proportionality of body surface area and pharyngeal surface area, this dose would be equivalent to a single dose of 5.4 g of Bonjela Teething Gel for a three month old child.

It is most unlikely, even with misuse or excessive application of Bonjela Teething Gel, that the large amounts of Lidocaine hydrochloride or cetalkonium chloride required to produce clinically-relevant toxic effects would be reached. In the event of overdose, use should be discontinued and a doctor consulted.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Lidocaine hydrochloride is an established local anaesthetic agent which produces tissue insensitivity by virtue of its ability to impede the inward flux of sodium ions, thus preventing transmission of the nerve impulse.

Cetalkonium chloride is a quatemary ammonium antimicrobial agent, being bactericidal towards both gram positive and gram negative organisms but with preference for the former.


Go to top of the page
5.2 Pharmacokinetic properties

Lidocaine is highly lipophilic resulting in rapid passage through mucous membranes, which is confirmed by human studies showing a Tmax of approximately 50 minutes following application of a 2% solution to the intact oral mucosa.

Metabolism is virtually complete by the hepatic route, undergoing three transformations, oxidative-n-dealkylation, hydrolysis and hydroxylation.

In neonates a T½ of 3-5 hours has been reported following intrathecal administration of Lidocaine to the mother; the elimination following topical application to the oral mucosa is likely to be of the same order.


Go to top of the page
5.3 Preclinical safety data

No preclinical findings of relevance have been reported.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Ethanol 96%, glycerol, hypromellose 4500, sodium cyclamate 1969, banana flavour E13174 and purified water.


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

Two years.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C.


Go to top of the page
6.5 Nature and contents of container

Internally lacquered collapsible aluminium tube with membrane seal fitted with a polyethylene wadless cap. Pack sizes: 10g, 15g and 15 g plus teether.


Go to top of the page
6.6 Special precautions for disposal and other handling

Apply a small amount of gel with a clean little finger to the affected area and rub in gently.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Reckitt Benckiser Healthcare (UK) Limited,

Dansom Lane,

Hull,

HU8 7DS

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 0063/0048.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

24 April 1995.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

28/04/2006



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/23319/SPC/


Active Ingredients/Generics

 
   cetalkonium chloride
   lidocaine hydrochloride